dr perlmutter glutathione Jeffrey A. Perlmutter, MD Dr. David Perlmutter, MD |

Collectively, targeting SIRT1 in neuro diseases offers promising therapeutic avenues

What to expect: Improved sleep depth and quality Subtle energy improvements Possible injection site reactions (mild, temporary) Phase 2: Optimization (Months 2-3) Benefits become more noticeable as growth hormone levels optimize

Journal of Clinical Medicine, 8 (11)

Final Thoughts BPC-157 (Body Protection Compound-157) continues to capture scientific interest for its unique structure, stability, and potential role in biological repair processes

Zinc Anti-inflammatory and antimicrobial boost for breakout-prone or inflamed skin, dosed to meaningful therapeutic levels